Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients

被引:24
|
作者
Klug, C
Wutzl, A
Kermer, C
Voracek, M
Kornek, G
Selzer, E
Glaser, C
Poeschl, PW
Millesi, W
Ewers, R
机构
[1] Med Univ Vienna, Vienna Gen Hosp, Dept Craniomaxillofacial & Oral Surg, A-1090 Vienna, Austria
[2] Univ Vienna, Dept Psychol, Div Res Methods & Differential Psychol, Vienna, Austria
[3] Med Univ Vienna, Div Oncol, Dept Internal Med 1, A-1090 Vienna, Austria
[4] Med Univ Vienna, Dept Radiotherapy, Ctr Excellence Clin & Expt Oncol, A-1090 Vienna, Austria
[5] Hosp Lainz, Ludwig Boltzmann Inst Gerostomatol, Inst Oral & Maxillofacial Surg & Dent, Vienna, Austria
关键词
chemotherapy; concurrent; multimodal therapy; oral cancer; outcome; radiotherapy;
D O I
10.1016/j.ijom.2004.04.003
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
To analyse survival and locoregional control in patients with advanced oral and oropharyngeal squamous cell carcinoma (SCC) after multimodal therapy with preoperative radiochemotherapy (RCT) and radical surgery. We included in this analysis 222 patients who underwent multimodal therapy between 1990 and 2000. Eligible were patients with UICC disease stages II-IV (T2: 33.3%; T3: 12.6%; T4: 54.1%; NO: 45.9%; NI: 17.6%; N2: 33.3%; N3: 3.2%; stage 11: 21.1%; stage 111: 14.9%; stage IV: 64%). Patients received preoperative radiochemotheraq consisting of Mitomycin C (15-20 mg/m(2), day 1) plus 5-Fluorouracil (750 mg/m(2) /24 h-infusion, days 1-5) and concomitant radiotherapy for a total dose of 50 Gy. Radical locoregional en bloc-resection according to the pretherapeutic tumour extension was carried out in all patients. After a median surveillance period of 72.3 months (24-152 months), 131 patients (59%) were alive, and 91 (41%) patients died; 12 (5%) of them died postoperatively, 46 (21%) due to tumour recurrence, and 33 (15%) deaths were not directly related to the primary tumour. Overall survival probability was 76% after 2 years, and 62% after 5 years. Two- and 5-year local control probability were 88 and 81%, respectively. Regarding the high percentage of stage IV disease in the reported patients, the multimodal concept is an effective therapy offering excellent survival and local control probability.
引用
收藏
页码:143 / 148
页数:6
相关论文
共 50 条
  • [31] Retrospective evaluation of a system model of the BCL2 family of proteins as a predictive and prognostic biomarker for the clinical outcome of stage II-IV colorectal cancer patients
    Lindner, Andreas U.
    Salvucci, Manuela
    Cremona, Mattia
    Monsefi, Naser
    Curry, Sarah
    Morgan, Clare
    Resler, Alexa
    O'Byrne, Robert
    Bacon, Orna
    Stuehler, Michael
    Flanagan, Lorna
    Wilson, Richard
    Johnston, Patrick G.
    Salto-Tellez, Manuel
    Camilleri-Broet, Sophie
    McNamara, Deborah A.
    Hennessy, Bryan T.
    Kay, Elaine W.
    Laurent-Puig, Pierre
    Van Schaeybroeck, Sandra
    Prehn, Jochen H. M.
    CANCER RESEARCH, 2016, 76
  • [32] Compartment Surgical resection for truly advanced oral-oropharyngeal-paranasal sinus cancer: New concept and early outcome
    Trivedi, N.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S7 - S7
  • [33] Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
    Kathrin Dellas
    Thomas Höhler
    Thomas Reese
    Florian Würschmidt
    Erik Engel
    Claus Rödel
    Wolfgang Wagner
    Michael Richter
    Dirk Arnold
    Jürgen Dunst
    Radiation Oncology, 8
  • [34] LEUsefulness of the Number of Elevated Preoperative Tumor Markers in Pancreatic Cancer Patients after Radical Resection
    Ishii, Masatsugu
    Mise, Minori
    Aoki, Yuichi
    Shirakawa, Hirofumi
    Tomikawa, Moriaki
    Ozawa, Iwao
    Hishinuma, Shoichi
    Ogata, Yoshiro
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S316 - S317
  • [35] Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer
    Dellas, Kathrin
    Hoehler, Thomas
    Reese, Thomas
    Wuerschmidt, Florian
    Engel, Erik
    Roedel, Claus
    Wagner, Wolfgang
    Richter, Michael
    Arnold, Dirk
    Dunst, Juergen
    RADIATION ONCOLOGY, 2013, 8
  • [36] Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml
    Urakami, Shinji
    Yonese, Junji
    Yamamoto, Shinya
    Yuasa, Takeshi
    Kitsukawa, Shinichi
    Numao, Noboru
    Kubo, Yuichi
    Ito, Masaya
    Sukegawa, Gen
    Yasuda, Yosuke
    Ishikawa, Yuichi
    Fukui, Iwao
    UROLOGIA INTERNATIONALIS, 2011, 87 (02) : 175 - 181
  • [37] External validation of a rectal cancer outcome prediction model with a cohort of patients treated with preoperative radiochemotherapy and deep regional hyperthermia
    Zwirner, K.
    Bonomo, P.
    Lamprecht, U.
    Zips, D.
    Gani, C.
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2018, 34 (04) : 455 - 460
  • [38] Expression of class III β tubulin in cervical cancer patients administered preoperative radiochemotherapy:: Correlation with response to treatment and clinical outcome
    Ferrandina, Gabriella
    Martinelli, Enrica
    Zannoni, Gian Franco
    Distefano, Mariagrazia
    Paglia, Amelia
    Ferlini, Cristiano
    Scambia, Giovanni
    GYNECOLOGIC ONCOLOGY, 2007, 104 (02) : 326 - 330
  • [39] Safety and feasibility of in-hospital early chemotherapy initiation after surgery in patients with stage II-IV colon cancer
    Kang, Jeonghyun
    Chong, Su-Weon
    Park, Eun Jung
    Baik, Seung Hyuk
    Lee, Kang Young
    MEDICINE, 2019, 98 (18)
  • [40] 18F-alfatide PET/CT may predict the survival of patients with stage II-IV lung cancer
    Wei, Yuchun
    Qin, Xueting
    Luan, Xiaohui
    Zhou, Yue
    Yuan, Shuanghu
    Yu, Jinming
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61